Ipsen is seeking partnerships in endocrinology
Ipsen business development
Ipsen is a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000.
The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The Group complements implementation of its internal Research and Development programme by entering into partnership agreements with university teams and pharmaceutical and biotechnology companies. These partnerships help the Group to gain access to cutting-edge technologies in complex areas of expertise.
The Group is constantly looking to forge high-quality, complementary and longlasting marketing and Research and Development partnerships.
In pituary disorders, Ipsen is involved in several research programmes, chiefly in pituary adenomas, such as as acromegaly. The Group is also continuing its efforts to identify second-generation somatostatin analogues and growth hormone antagonists. Ipsen is currently investigating molecules with a broader spectrum of activity and hopes that they will not only provide a symptomatic treatment for acromegaly, but also offer the possibility of reducing tumour size, thereby eleminating many of the limitations associated with existing treatments (dopastatin).
Ipsen is also exploring the role of certain peptide hormones (Ghrelin, MSH/MC4) in regulating food intake with the priority objective of treating cachexia (lack of appetite) which is often the cause of functional disorders in the elderly, cancer patients and patients with chronic illnesses. The Group is continuing to pursue the programmes it initiated in 11-ßHSD enzyme inhibitors with a view to developing a therapy for the related metabolic syndromes associated in obese patients with hyperinsulinemia, which principally manifests itself in the form of greater cardiovascular risks. In conjunction with Asterion, the Group is also continuing to develop analogues of growth hormone antagonists and endocrinology.